Form 10-Q · Quarterly report
Ciena 10-Q, filed Sep 3, 2026
- Filed
- CIK
- 0000936395
- Accession no.
- 0001628280-26-060361
Summary
This quarterly filing shows Ciena's third-quarter fiscal 2026 revenue rose 37% year over year to $1.7 billion, with gross margin up to 45.4% from 41.3%, as orders significantly exceeded revenue amid AI- and cloud-driven capital expenditures and an industry-wide constrained supply environment. Ciena completed a $2.9 billion convertible note offering during the quarter and used the proceeds to repay its term loan.
Key points
- Third-quarter fiscal 2026 revenue was $1.67 billion, up 37.0% from $1.22 billion a year earlier, and first-nine-month revenue rose 36.6% to $4.67 billion.
- Optical Networking revenue rose 46.1% in the quarter, driven by 6500 Reconfigurable Line Systems, Waveserver systems, and coherent pluggable transceivers.
- Operating expense grew to $458 million from $430 million, including $237 million of research and development spending, up 12%.
- Ciena ended the first nine months of fiscal 2026 with $2.8 billion in cash, cash equivalents, and investments, and cash from operations of $684 million versus $435 million a year earlier.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview We are a network technology company, providing hardware, software, and services to a wide range of network operators and enabling enhanced network capacity, service delivery, and automation. Our solutions support network traffic across a wide range of applications, including cloud, voice, video, data, and artificial intelligence (“AI”). Our network solutions are used globally by cloud providers, service providers, and other network operators across multiple industry verticals. The markets into which we sell are dynamic and characterized by a high rate of change. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.